Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARCH: Selinexor + Dexamethasone in Refractory Multiple Myeloma
NCT03944057Phase 2Completed
- Sponsor
- Antengene
- Start
- Sep 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by Antengene. Primary endpoint: Overall Response Rate at 12 months. Started Sep 2019; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03944057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944057.